Improved Survival of HER2-Positive Metastatic Breast Cancer in Routine Care

摘要: Purpose: Targeted therapy directed against HER2 has improved the outcome of patients with HER2-positive metastatic breast cancer in prospective clinical trials. No data are available how anti-HER2-therapy influenced survival unselected who receive treatment routine care. Methods: Data 118 subsequent were treated a community-based oncology group practice between 1995 and 2010 analyzed retrospectively. Results: Median age at initial diagnosis metastasis was 58 years (33-92). Twenty-two percent metastasized cancer, seventy-eight developed metastases course disease. Distribution sites was: 23% bone, 58% visceral, 5% CNS, 10% lymph nodes, 4% other. Hormone receptor positive 68% negative 31%. Palliative consisted antihormonal 56%, chemotherapy 90% radiotherapy 50%. Seventy-five received consisting trastuzumab 80% lapatinib 1%, 19% + sequentially. Twenty-five no anti-HER2-therapy. overall since 34 months (0-277+). Conclusion: It could be shown that, compared to historical controls, targeted prolongs